DE602004008291D1 - Substituierte piperidine als histamin-h3-rezeptorliganden - Google Patents

Substituierte piperidine als histamin-h3-rezeptorliganden

Info

Publication number
DE602004008291D1
DE602004008291D1 DE602004008291T DE602004008291T DE602004008291D1 DE 602004008291 D1 DE602004008291 D1 DE 602004008291D1 DE 602004008291 T DE602004008291 T DE 602004008291T DE 602004008291 T DE602004008291 T DE 602004008291T DE 602004008291 D1 DE602004008291 D1 DE 602004008291D1
Authority
DE
Germany
Prior art keywords
histamine
receptor ligands
substituted piperidines
piperidines
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602004008291T
Other languages
English (en)
Other versions
DE602004008291T2 (de
Inventor
J M Bailey
Gordon Bruton
Anthony Huxley
Peter Henry Milner
B S Orlek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0316893A external-priority patent/GB0316893D0/en
Priority claimed from GB0411167A external-priority patent/GB0411167D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE602004008291D1 publication Critical patent/DE602004008291D1/de
Application granted granted Critical
Publication of DE602004008291T2 publication Critical patent/DE602004008291T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DE602004008291T 2003-07-18 2004-07-16 Substituierte piperidine als histamin-h3-rezeptorliganden Expired - Fee Related DE602004008291T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0316893A GB0316893D0 (en) 2003-07-18 2003-07-18 Novel compounds
GB0316893 2003-07-18
GB0411167A GB0411167D0 (en) 2004-05-19 2004-05-19 Novel compounds
GB0411167 2004-05-19
PCT/EP2004/008061 WO2005014571A1 (en) 2003-07-18 2004-07-16 Substituted piperidines as histamine h3 receptor ligands

Publications (2)

Publication Number Publication Date
DE602004008291D1 true DE602004008291D1 (de) 2007-09-27
DE602004008291T2 DE602004008291T2 (de) 2008-05-08

Family

ID=34137741

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004008291T Expired - Fee Related DE602004008291T2 (de) 2003-07-18 2004-07-16 Substituierte piperidine als histamin-h3-rezeptorliganden

Country Status (9)

Country Link
US (1) US20060247227A1 (de)
EP (1) EP1646620B1 (de)
JP (1) JP2006528147A (de)
AR (1) AR045999A1 (de)
AT (1) ATE370135T1 (de)
DE (1) DE602004008291T2 (de)
ES (1) ES2291913T3 (de)
TW (1) TW200514781A (de)
WO (1) WO2005014571A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007010350A1 (en) * 2005-07-19 2007-01-25 Pfizer Products Inc. Synthesis of therapeutic diphenyl ethers
CA2606004A1 (en) 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl ketones and related analogues
US8653262B2 (en) 2007-05-31 2014-02-18 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists and uses thereof
JP2010540523A (ja) * 2007-09-28 2010-12-24 シェーリング コーポレイション ヒスタミン受容体アンタゴニストとしてのオキシピペリジン誘導体
PL2379525T3 (pl) 2008-12-19 2016-01-29 Centrexion Therapeutics Corp Cykliczne pirymidyno-4-karboksamidy jako antagoniści receptora CCR2 do leczenia stanów zapalnych, astmy oraz COPD
JP5632014B2 (ja) 2009-12-17 2014-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト及びこれらの使用
EP2569295B1 (de) 2010-05-12 2014-11-19 Boehringer Ingelheim International GmbH Neue ccr2-rezeptorantagnonisten, herstellungsverfahren dafür und verwendung davon als medikamente
EP2569298B1 (de) 2010-05-12 2015-11-25 Boehringer Ingelheim International GmbH Neuartige ccr2-rezeptorantagnonisten, herstellungsverfahren dafür und verwendung davon als medikamente
JP5647339B2 (ja) 2010-05-17 2014-12-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２アンタゴニスト及びこれらの使用
CN102260277B (zh) 2010-05-24 2013-07-24 中国科学院上海药物研究所 新型苯并噁嗪噁唑烷酮类化合物及其制备方法和用途
EP2576542B1 (de) 2010-05-25 2015-04-22 Boehringer Ingelheim International GmbH Zur Behandlung von Atemwegs-, Schmerz,- Immun- und cardoivaskulären Erkrankungen geeignete cyclische Amidderivate von Pyridazin-3-carbonsäuren
US8962656B2 (en) 2010-06-01 2015-02-24 Boehringer Ingelheim International Gmbh CCR2 antagonists
CN103201267B (zh) 2010-07-29 2016-08-17 里格尔药品股份有限公司 Ampk-激活性杂环化合物以及其使用方法
EP2731941B1 (de) 2011-07-15 2019-05-08 Boehringer Ingelheim International GmbH Neuartige und selektive ccr2-antagonisten
CA2863022A1 (en) * 2012-01-16 2013-07-25 Glaxosmithkline Intellectual Property Development Limited Therapeutic uses
CN104114538B (zh) * 2012-01-16 2016-04-13 葛兰素史克知识产权发展有限公司 治疗用途
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
EP2647377A1 (de) 2012-04-06 2013-10-09 Sanofi Verwendung eines H3-Rezeptorantagonisten zur Behandlung von Morbus Alzheimer
WO2017004537A1 (en) 2015-07-02 2017-01-05 Centrexion Therapeutics Corporation (4-((3r,4r)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2r,6s)-6-(p-tolyl)tetrahydro-2h-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
EP3383853B1 (de) * 2015-12-01 2020-11-04 Merck Sharp & Dohme Corp. Homobispiperidinylderivate als leber x rezeptor (lxr) beta agonisten zur behandlung von z.b. alzheimer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
AU2002253929A1 (en) * 2001-02-08 2002-09-24 Schering Corporation Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders
WO2003031432A1 (en) * 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
EP1552842A1 (de) * 2002-06-07 2005-07-13 Kyowa Hakko Kogyo Co., Ltd. Bizyklische pyrimidin-derivate

Also Published As

Publication number Publication date
EP1646620B1 (de) 2007-08-15
EP1646620A1 (de) 2006-04-19
TW200514781A (en) 2005-05-01
DE602004008291T2 (de) 2008-05-08
AR045999A1 (es) 2005-11-23
ES2291913T3 (es) 2008-03-01
US20060247227A1 (en) 2006-11-02
JP2006528147A (ja) 2006-12-14
ATE370135T1 (de) 2007-09-15
WO2005014571A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
ATE370135T1 (de) Substituierte piperidine als histamin-h3- rezeptorliganden
IL180548A0 (en) Piperidine derivatives as histamine h3 receptor ligands
HK1247610A1 (zh) 作為nk1拮抗劑的哌啶衍生物
ATE450526T1 (de) Als antagonisten von histamin h3 geeignete piperidinderivate
ATE387202T1 (de) Pyrrolidinderivate als histaminrezeptor-liganden
ATE529112T1 (de) 1-(4-piperidinyl)benzimidazolone als histamin h3 antagonisten
ATE448217T1 (de) Substituierte piperidine als renin-inhibitoren
ATE494285T1 (de) Muscarinische acetylcholin-rezeptor-antagonisten
ATE389406T1 (de) 1-(4-piperidinyl)benzimidazole als histamin h3 antagonisten
ATE479681T1 (de) Substituierte piperidine
ATE420863T1 (de) Substituierte piperidinverbindungen zur verwendung als h3 histaminerezeptorantagonisten
DK1682142T3 (da) M3-muscarin-acetylcholin-receptor-antagonister
ATE461191T1 (de) N-substituierte 2-oxodihydropyridinderivate als npy antagonisten
DK1515969T3 (da) Spiroindolinpiperidinderivater
IL180547A0 (en) Novel piperidine derivatives as histamine
ATE344798T1 (de) Als histamin-h3-antagonisten geeignete indolderivate
DK1773810T3 (da) Hidtil ukendte 4-benzylidenpiperidinderivater
DE60320529D1 (de) Chinolinderivate als npy antagonisten
ATE471321T1 (de) Substituierte piperidine als renin-inhibitoren
DE60302137D1 (de) Piperidinderivate
DE60314170D1 (de) Substituierte 4-amino-1-(pyridylmethyl)piperidine zur verwendung als muscarinrezeptor-antagonisten
DE602004015610D1 (de) 3-fluoro-piperidine als nmda/nr2b antagonisten
ATE364602T1 (de) 4-(aminomethyl)-piperidinbenzamide als 5ht4 - antagonisten
ATE373654T1 (de) Thiazolderivate als npy-rezeptorantagonisten
ATE377008T1 (de) Imidazolderivate als glutamatrezeptorantagonisten

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: HUXLEY, ANTHONY, HARLOW ESSEX CM19 5AW, GB

Inventor name: BRUTON, GORDON, HARLOW ESSEX CM19 5AW, GB

Inventor name: ORLEK, B. S., HARLOW ESSEX CM19 5AW, GB

Inventor name: MILNER, PETER HENRY, HARLOW ESSEX CM19 5AW, GB

Inventor name: BAILEY, J. M., HARLOW ESSEX CM19 5AW, GB

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee